New drug approved for ROS1 lung cancer after earlier treatment
Original title: Jideytro (zidesamtinib) for previously treated ros1-positive non-small cell lung cancer: a new era in post-tki therapy.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
The FDA has approved it, so a doctor can prescribe it today.
The short version
The FDA approved a new drug for ROS1 lung cancer that grew after earlier treatment.
What was studied. This report covers a new drug called zidesamtinib, sold as Jideytro. It was tested in a trial called ARROS-1 in adults whose ROS1-positive lung cancer had already been treated with another ROS1 drug.
What they found. The people in the trial had already had a lot of treatment. Some had cancer that had spread to the brain. The drug shrank tumors, and those responses lasted. Few people had to stop taking it. The FDA approved it on 22 July 2026.
What this means, and what it doesn't
What it could mean: If an earlier ROS1 drug stopped working, this is a new option a doctor can prescribe now. It was built to reach the brain, which matters if the cancer spread there. It also still works against some gene changes that make other ROS1 drugs fail. Ask your cancer doctor if it fits your case.
What it doesn't mean: This is not a cure. The drug has not been tested head to head against the other ROS1 drugs, so nobody knows yet if it works better than they do. It only helps lung cancer driven by a ROS1 gene change. It is not a treatment for brain tumors that start in the brain, even though it can reach the brain.
Source: PubMed, September 7, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.